ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings, we are dedicated to turning every cancer patient’s genetic information into actionable resolutions. Our NGS platform coupled with sophisticated bioinformatics tools and curated proprietary databases enable us to deliver reliable results for clinical and research purposes, and our data visualization technologies make the scientific results easily understandable for everyone. Our clinical services range from cancer prevention, early detection, treatment selection and disease monitoring, ACTDrug®+ ACTOnco®+, ACTImmune™, ACTColon™, ACTBreast™, ACTGastric™, ACTLung™. Our genomic assays, ACTDrug® and ACTOnco®, offer comprehensive cancer genomic profiling and treatment options for patients with cancer; and provide insights to biomarker discovery and patient stratification for clinical trials. Embracing the future of Precision Medicine. ACT Genomics, your best partner http://www.actgenomics.com/en/
